Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2023.03.15

Kilo lab

Sai Life Sciences sets up GMP Kilo Lab in Alderley Park, Manchester, UK

Sai Life Sciences today announced the setting up of a GMP Kilo Lab at its facility in Alderley Park, Manchester, UK. The new GMP Kilo Lab will enable Sai Life Sciences to offer drug substance and intermediates supplies ranging from gram to kilogram quantities to meet customer clinical requirements at an accelerated pace.

Making the announcement, Sauri Gudlavalleti, COO of Sai Life Sciences said, “The new lab, located closer to our customers, has been set up with comprehensive cGMP controls and world-class infrastructure. The facility will combine with our expertise in route scouting, process chemistry and scale-up, to help our partners accelerate their drug discovery and development journeys by reducing time to first-in-human clinical trials.”

Being offered both, as a standalone facility as well as part of an integrated service together with its capabilities in India, the lab consists of one process stream including two vessels of up to 35 L capacity with provision to add more streams in future. It is supported with associated contained filtration & drying equipment and is engineered to provide containment level of 1μg/m3. The lab also offers analytical method validation and analytical services to support batch release, in additional to stability studies to enable rapid regulatory filing.

Earlier, in July 2020, the company had opened a new Centre of Excellence (CoE) in Process Chemistry R&D in Alderley Park, Manchester, to help accelerate the NCE development programmes of global innovator customers. This centre has since grown to become a reliable partner to many innovator companies across the world, providing high quality chemistry, non GMP delivery, and successful technology transfer to our sites in India for scale-up.

Over the past three years, the company has made investments of over US$120M as part of its SaiNxt initiative, to augment capacity, scale up operations, expand into new geographies, grow its scientific talent base, and raise the overall bar for quality, compliance, and performance.

Share article

More News

2025.02.07

Sai Life Sciences headquarters, symbolizing innovation and growth, featured in a blog post about the company's strong quarterly report performance.

Sai Life Sciences Limited reports robust quarterly results

Revenue grows by 15%; Net Profit up 36% year-on-year Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused, Contract Research and Development Organization (CRDMO) today announced its financial results for the third quarter and nine months ended December 31, 2024. Financial Performance: Particulars (₹ crores) Q3FY25 Q3FY24 YoY% 9MFY25 9MFY24 YoY% Revenue […]
Read more

2025.01.01

Before and after comparison of the historic Manchirevula stepwell restoration by Sai Life Sciences, showcasing transformation from a neglected site to a well-maintained water body near a temple.

Sai Life Sciences completes restoration of historic Manchirevula stepwell

As part of its Corporate Social Responsibility (CSR) initiative, Sai Life Sciences, in collaboration with the Society for Advancement of Human Endeavours (SAHE), completed the restoration of the historic stepwell dating back to the 17th century at the Sri Venugopala Swamy temple premises, located in Manchirevula, Hyderabad. The Manchirevula Stepwell Restoration Project was undertaken with […]
Read more

2024.10.28

Advanced manufacturing facility at Sai Life Sciences, showcasing state-of-the-art equipment and quality control, featured in a blog post about receiving Establishment Inspection Reports (EIRs) from the USFDA.

Sai Life Sciences receives EIRs from USFDA for India R&D & Manufacturing facilities

Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO)[1], announced that it has received Establishment Inspection Reports (EIR) from the US Food and Drug Administration (USFDA) for its R&D (Unit II, Hyderabad), and Manufacturing (Unit IV, Bidar) sites in India. The General Good Manufacturing Practices (GMP) audit was conducted at the […]
Read more

2024.10.07

Sai Life Sciences' eco-friendly campus with green landscaping and modern architecture at sunset, featured in a blog post about the company's 2024 Sustainability Report

Sai Life Sciences releases Sustainability Report 2024

Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO)[1], published its Sustainability Report for 2023-2024. Aligned with the Global Reporting Initiative (GRI) Universal Standards 2021 framework, this fifth edition of the Sustainability Report is based on the theme, ‘Synergising Sustainability, Performance and Growth.’ The full report can be read here. Making […]
Read more

2024.08.09

Sai Life Sciences scientist accessing a -40.2°C ultra-low temperature storage unit as part of the advanced Compound Management process, enhanced by the in-house CORAL software application.

Sai Life Sciences elevates Compound Management process with in-house software application, CORAL

Compound management is a vital function in pharmaceutical research. A streamlined environment can bring significant value to the process in the form of productivity and efficiency. Recognizing the importance of this function, we have made our Compound Management suite for Discovery services smarter with the introduction of an in-house software application, Compound Organization and Registration […]
Read more